Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221044 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CYP3A4GAAMEN1KMT2A | |
| SCHEMBL3827955 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP3A4GAAMEN1KMT2A | |
| SCHEMBL2760405 | 0.78 | ALDH1A1 (0.50) | ALDH1A1CYP3A4GAAMEN1KMT2A | |
| SCHEMBL4796757 | 0.78 | GRM2 (0.44) | ALDH1A1CYP3A4GAAMEN1KMT2A | |
| SCHEMBL1653731 | 0.78 | ALDH1A1 (0.65) | ALDH1A1CYP3A4GAAMEN1KMT2A | |
| SCHEMBL11182921 | 0.77 | GAA (0.62) | ALDH1A1CYP3A4GAAKMT2ASMN1; SMN2 | |
| SCHEMBL4803221 | 0.75 | ALDH1A1 (0.43) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19485375 | 0.75 | CYP3A4 (0.53) | ALDH1A1CYP3A4MEN1KMT2AHPGD | |
| SCHEMBL19906474 | 0.75 | P2RX7 (0.50) | ALDH1A1CYP3A4HPGDSMN1; SMN2LMNA | |
| SCHEMBL219172 | 0.74 | ALDH1A1 (0.44) | ALDH1A1CYP3A4MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091941-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-23 | — | — | EP | disclosed |
| EP-2091941-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-23 | — | — | EP | disclosed |
| US-8088783-B2 | MAPK/ERK kinase inhibitors | DONG QING (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088783-B2 | MAPK/ERK kinase inhibitors | DONG QING (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK4, MAPK6 | ALDH1A1 1803/4885CYP3A4 2213/4885GAA 2827/4885 |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2921/4885CYP3A4 1224/4885GAA 2792/4885 |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2921/4885CYP3A4 1224/4885GAA 2792/4885 |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK6, MAPK4 | ALDH1A1 1553/4885CYP3A4 1682/4885GAA 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.